[An update on the management of Raynaud's phenomenon].
Basic knowledge of clinical management of Raynaud's phenomenon was established and reviewed. Body protection against cold weather and the avoiding of all activities which cause the setting off of the ischemic episodic trigger are the first step in the therapy for this type of patient. Medical treatment includes vasoactive drugs and other drugs which act against the different factors such as plasmapheresis, sympathectomy and electric neurostimulation must be reserved for patients with severe vascular symptoms.
Rodríguez-García
J L
JL
Servicio de Medicina Interna, Hospital Ramón y Cajal, Madrid.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001340:Autonomic Nerve Block; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D006801:Humans; D010956:Plasmapheresis; D011453:Prostaglandins / Q000627:therapeutic use; D011928:Raynaud Disease / Q000628:therapy*; D012702:Serotonin Antagonists / Q000627:therapeutic use; D013562:Sympathectomy; D004561:Transcutaneous Electric Nerve Stimulation; D014665:Vasodilator Agents / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D011453:Prostaglandins; D012702:Serotonin Antagonists; D014665:Vasodilator Agents
Actualizaciones en el manejo del fenómeno de Raynaud.